Reduction in Depressive Symptoms in People who Inject Drugs who Are Cured of Hepatitis C Virus Infection: The HERO Study

Author:

Pericot-Valverde Irene1ORCID,Lopes Snehal S2,Nahvi Shadi3,Thrasher James F4,Karasz Alison5ORCID,Taylor Lynn E6,Mehta Shruti H7,Lum Paula J8,Tsui Judith I9,Page Kimberly10ORCID,Feinberg Judith11ORCID,Kim Arthur Y12,Norton Brianna L3,Arnsten Julia H3,Fernandez-Artamendi Sergio13,Heo Moonseong2ORCID,Litwin Alain11415ORCID,Litwin Alain H,Heo Moonseong,Pericot-Valverde Irene,Walker Hagan,Coleman and Ashley,Mehta Shruti H,Borsuk Courtney,Dickerson Brian,Falade-Nwulia Oluwaseun,Fingerhood Michael,Haselhuhn Taryn,Mason Angela,Moon Juhi,Olsen Yngvild,Walters and Vickie,Kim Arthur Y,Roche Jillian M,Schmitt William,Lijewski Virginia,Pitts Anita,Raji Syeda,Silva Taniya,Evans Fiona,Koene Hope,Brown Joelle,Norton Brianna,Agyemang Linda,Arnsten Julia,Karasz Alison,Meissner Paul,Lora Kiara,Hidalgo Jennifer,Soloway Irene,Jefferson Karen,Wong Joyce,Kermack Andrea,Stein Melissa,Joseph Gilian,London Karyn,Allen Lincoln,Marte Venecia,Vera Tatiana,Alvarez and Romy,Mckee M Diane,Lum Paula J,Stein Ellen S,Luetkemeyer Anne F,Cullen Caycee,Gill Gurjot,Tierney Hannah,Shapiro Scott,Azari Soraya,Eveland Joanna,Berrner Daniel,Grey Pauli,Akerley and Jordan,Page Kimberly,Wagner Katherine,Davis Herbert,Murray-Krezan Cristina,Jacobsohn Vanessa,Anderson Jessica,Taylor Lynn E,Tashima Karen,Sprecht-Walsh Sophie,Thomas Aurielle,Hordes Melissa,McGregor Danielle,Duryea Patrick,Weenig and Kathryn,Tsui Judith I,Blalock Kendra L,Kim Hyang Nina,Ramchandani Meena S,James Jocelyn R,Peavy K Michelle,Grekin Paul,Ninburg and Michael,Feinberg Judith,Wilkinson Samuel,Thomas Danielle,Kelley Lacey,Calkins Andrea,Henry Gabrielle,

Affiliation:

1. Department of Psychology, Clemson University , Clemson, South Carolina , USA

2. Department of Public Health Sciences, Clemson University , Clemson, South Carolina , USA

3. Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine , Bronx, New York , USA

4. Department of Health Promotion, Education, and Behavior, Arnold School of Public Health, University of South Carolina , Columbia, South Carolina , USA

5. Department of Family Medicine & Community Health, University of Massachusetts , Worcester, Massachusetts , USA

6. College of Pharmacy, University of Rhode Island . Kingston, Rhode Island , USA

7. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health , Baltimore, Maryland , USA

8. Department of Medicine, University of California , San Francisco, San Francisco, California , USA

9. Division of General Internal Medicine, University of Washington , Seattle, Washington , USA

10. Department of Internal Medicine, University of New Mexico Health Sciences Center , Albuquerque, New Mexico , USA

11. Department of Behavioral Medicine & Psychiatry and Department of Medicine, Infectious Diseases, West Virginia University School of Medicine , Morgantown, West Virginia , USA

12. Division of Infectious Diseases, Massachusetts General Hospital and Harvard Medical School , Boston, Massachusetts , USA

13. Department of Personality, Assessment, and Psychological Treatment, Universidad de Sevilla , Seville , Spain

14. Department of Medicine, University of South Carolina School of Medicine , Greenville, South Carolina , USA

15. Department of Medicine, Prisma Health , Greenville, South Carolina , USA

Abstract

Abstract Background Depressive symptoms are prevalent among people who inject drugs (PWID) and people with hepatitis C virus (HCV). We examined changes in depressive symptoms among HCV-infected PWID following direct-acting antiviral treatments to evaluate whether these changes differed by history of depressive symptoms, substance use, or HCV treatment outcome. Methods We conducted a secondary analysis of the HERO Study (NCT02824640), a pragmatic randomized clinical trial among PWID, to test the effectiveness of HCV care models. Depressive symptoms (primary outcome) were measured using the Patient Health Questionnaire (PHQ-9) at baseline, end of treatment (EOT), and at follow-up 12 and 24 weeks after EOT. Sustained virologic response (SVR) was defined as undetectable HCV RNA at ≥12 weeks following EOT. Baseline drug use was defined as having a positive urine screening test for amphetamine, methamphetamine, benzodiazepine, cocaine, cannabis, opiate, or oxycodone. Results The sample (n = 498) was 72.3% male, 64.2% White, and on average 43.9 years old. In patients who achieved SVR (F(3432) = 4.58; P = .004) and those with drug use at baseline (F(3478) = 5.11; P < .01), PHQ-9 scores significantly declined over time, with scores lower at EOT and both follow-ups as compared with baseline. Mean PHQ-9 scores at EOT and follow-ups were significantly lower than at baseline, except for those with no depression or mild depression at baseline. Conclusions This study showed that HCV treatment in PWID is associated with sustained declines in depression up to 24 weeks post-treatment among those who achieve SVR and that drug use does not interfere with improvement in depressive symptoms.

Funder

Patient-Centered Outcomes Research Institute

Gilead Sciences

Quest Diagnostics

Monogram Biosciences

OraSure Technologies

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3